Disease relevance of ADCP1

• In the present study, we investigated ADCP levels in 37 colorectal adenocarcinomas and correlated the results with clinicopathological characteristics in individual carcinomas [1].
• Adenosine deaminase complexing protein (ADCP) expression and metastatic potential in prostatic adenocarcinomas [2].
• This suggests that immunohistochemical detection of ADCP might predict the biological behaviour of prostatic cancer [2].
• However, the occurrence of membranous ADCP immunoreactivity in the xenograft of a cell line (PC-EW), derived from a prostatic carcinoma metastasis, indicates that not only the tendency to metastasize modulates ADCP expression [2].
• Ten (29%) of 34 common epithelial ovarian carcinomas showed ADCP reactivity [3].

High impact information on ADCP1

• Glutaraldehyde-fixed membranes from rabbit kidney cortex were used to characterize binding of monomeric adenosine deaminase to the adenosine deaminase complexing protein [4].
• In the normal and hyperplastic prostate, ADCP was localized exclusively in the apical membrane and the apical cytoplasm of the glandular epithelial cells [2].
• Thus, the complement of the L-cell derived A9 or B82 mouse parent apparently prevents the expression of human ADCP in the interspecific somatic cell hybrids [5].
• In the a3, E36, or RAG hybrids the human ADCP expression was not prevented by the rodent genome and was found to be proportional to the degree of confluency of the cell in the culture as in the case of primary human fibroblasts [5].
• Incidentally, the involvement of chromosome 2, which carries a gene for adenosine deaminase complexing protein (ADCP), in the causation of ADA deficiency was excluded [6].

Chemical compound and disease context of ADCP1

• Correlation between tumor histology, steroid receptor status, and adenosine deaminase complexing protein immunoreactivity in ovarian cancer [3].

Biological context of ADCP1

• Assignment of adenosine deaminase complexing protein (ADCP) gene(s) to human chromosome 2 in rodent-human somatic cell hybrids [5].

Anatomical context of ADCP1

• High membrane ADCP concentrations were found in skin, renal cortex, gastrointestinal tract, and prostate [7].
• These data demonstrate that ADCP is present predominantly in exocrine glands and absorptive epithelia [7].
• In all 19 investigated tissues, except erythrocytes, ADCP was found by RIA in the soluble and membrane fractions [7].
• In serous sweat glands, convoluted tubules of renal cortex, bile canaliculi, gastrointestinal tract, lung, pancreas, prostate gland, salivary gland, gallbladder, mammary gland, and uterus, ADCP immunoreactivity was found confined to the luminal membranes of the epithelial cells [7].
• Immunohistochemical localization of adenosine deaminase complexing protein in intestinal mucosa and in colorectal adenocarcinoma as a marker for tumour cell heterogeneity [8].

Associations of ADCP1 with chemical compounds

• ADCP is a dimeric glycoprotein of about 200KD, for which the physiological role is still obscure [9].
• Adenosine deaminase complexing protein (ADCP) immunoreactivity was investigated in 40 ovarian tumors and correlated with clinicopathologic parameters, including tumor steroid receptor content [3].
• Furthermore, tumors that contained high levels of androgen receptors and tumors that did not contain estrogen receptors were more frequently ADCP positive (p less than 0.05) [3].

Analytical, diagnostic and therapeutic context of ADCP1

• The levels of adenosine deaminase (EC 3.5.4.4) and soluble ADCP were determined in tissue samples by, respectively, a spectrophotometric assay and an ADCP specific radioimmunoassay [1].
• The normal distribution of adenosine deaminase complexing protein (ADCP) in the human body was investigated quantitatively by ADCP-specific radioimmunoassay (RIA) and qualitatively by immunohistochemistry [7].

References